Print this article
- 03/15/2017

DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against Sinopharm Weiqida Pharmaceutical

Pharma Horizon

DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed lawsuits against Sinopharm Weiqida Pharmaceutical for patent infringement.


DSM Sinochem Pharmaceuticals announced that its wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd. filed lawsuits against Sinopharm Weiqida Pharmaceutical Co., LTD  (“Weiqida”) for patent infringement in both the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European Patent Number 1,610,766 B1 and in the High Court of Delhi at New Delhi for patent infringement of Indian Patent Number 247,301. These patents, which are owned by DSP, describe and claim amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.

By its complaint, DSP seeks an injunction to prevent the infringing manufacture, use, importation and sale of Weiqida’s amoxicillin active pharmaceutical ingredient in the Netherlands and India as well as any drug product that utilizes the active pharmaceutical ingredient.

Karl Rotthier, CEO at DSP said: “DSP has a world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology.  DSP will rigorously defend its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”